Hemophilia Home Treatment:<i>Economic Analysis and Implications for Health Policy</i>

Dennis Ross‐Degnan(Harvard Pilgrim Health Care), Louis M. Aledort(Icahn School of Medicine at Mount Sinai), Rosalie Bright(United States Food and Drug Administration), Jerry Avorn(Brigham and Women's Hospital), Rhonda L. Bohn(Brigham and Women's Hospital), Stephen B. Soumerai(Harvard Pilgrim Health Care)
International Journal of Technology Assessment in Health Care
January 1, 1995
10.1017/s0266462300006930
Cited by 34

Related Papers

Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial
|The Lancet|2008|862
Definitions in hemophilia. Recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis.
|PubMed|2001|803
Definitions in Hemophilia
|Thrombosis and Haemostasis|2001|772
A longitudinal study of orthopaedic outcomes for severe factor‐VIII‐deficient haemophiliacs
|Journal of Internal Medicine|1994|613
A More Uniform Measurement of Factor VIII Inhibitors
|Thrombosis and Haemostasis|1975|587